Metabolon's Quantose prediabetes tests available in Europe via partnership with Metdia Biotech

North Carolina-based Metabolon, Inc., has joined with Metdia Biotech, S.L. to commercialize its Quantose IR and Quantose IGT prediabetes tests in Europe. These laboratory-developed tests (LDTs) can be used in risk assessment, monitoring, and, with appropriate intervention, prevention of prediabetes and type 2 diabetes. Metdia will market the tests to hospitals and clinical laboratories in Spain, Portugal, France, the United Kingdom, Italy, Germany, Switzerland, Sweden, Norway, Denmark, Finland, the Netherlands, Belgium, and Austria.

Quantose IR is an LDT that reflects insulin resistance. This blood test is based on insulin and three non-glycemic biomarkers. Metabolon representatives say that it assesses risk of progression to prediabetes earlier than traditional glycemic measures such as hemoglobin A1c. By reflecting insulin resistance, Quantose IR provides clinicians with useful information that enables them to stratify patients by level of insulin sensitivity.

Quantose IGT is an LDT that reflects the degree of impaired glucose tolerance, a core metabolic defect in dysglycemia and a known risk factor for prediabetes. Quantose IGT may be used as an alternative to an oral glucose tolerance test (OGTT) or to identify patients who may be candidates for an OGTT.

“Licensing our Quantose IR and Quantose IGT technology to Metdia in Europe is an important next step in expanding the availability of these tests outside the United States,” says John Ryals, PhD, president and CEO of Metabolon. “Earlier this year, Quantose IR became commercially available in Mexico through Patia Biopharma. We are delighted to see our technology available in these two major markets.” Learn more about Quantose IR and Quantose IGT.